Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 585-598

  Yu, Jian ^a   Chen, Liguang ^a   Cui, Bing ^a   Widhopf Ii, George F ^a   Shen, Zhouxin ^b   Wu, Rongrong ^a   Zhang, Ling ^a   Zhang, Suping ^a   Briggs, Steven P ^b   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SECTION OF CELL AND DEVELOPMENTAL BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRMTUZUMAB; CYSTEINE; CYTOKINE; GUANINE; GUANINE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MONOCLONAL ANTIBODY; PROLINE RICH PROTEIN; RAC1 PROTEIN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT5A PROTEIN; ONCOPROTEIN; RAC1 PROTEIN, HUMAN; ROR1 PROTEIN, HUMAN; ROR2 PROTEIN, HUMAN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; HETEROOLIGOMERIZATION; KRINGLE DOMAIN; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROLINE RICH PROTEIN DOMAIN; PROTEIN EXPRESSION; ANIMAL; CANCER TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CHEMOTAXIS; HETEROGRAFTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS; RAC1 GTP-BINDING PROTEIN; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; WNT PROTEINS; WNT-5A PROTEIN;

EID: 84956954700     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83535     Document Type: Article

References (57)

1. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267(36):26181-26190.
2. Wilson C, Goberdhan DC, Steller H. Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc Natl Acad Sci U S A. 1993;90(15):7109-7113.
3. Forrester WC, Dell M, Perens E, Garriga G. A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature. 1999;400(6747):881-885.
4. Koga M, Take-uchi M, Tameishi T, Ohshima Y. Control of DAF-7 TGF-(alpha) expression and neuronal process development by a receptor tyrosine kinase KIN-8 in Caenorhabditis elegans. Development. 1999;126(23):5387-5398.
5. McKay SE, et al. Aplysia ror forms clusters on the surface of identified neuroendocrine cells. Mol Cell Neurosci. 2001;17(5):821-841.
6. Hikasa H, Shibata M, Hiratani I, Taira M. The Xenopus receptor tyrosine kinase Xror2 modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. Development. 2002;129(22):5227-5239.
7. Rodriguez-Niedenfuhr M, Prols F, Christ B. Expression and regulation of ROR-1 during early avian limb development. Anat Embryol (Berl). 2004;207(6):495-502.
8. Katoh M, Katoh M. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep. 2005;14(5):1381-1384.
9. Minami Y, Oishi I, Endo M, Nishita M. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn. 2010;239(1):1-15.
10. Oishi I, et al. Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells. 1999;4(1):41-56.
11. Al-Shawi R, Ashton SV, Underwood C, Simons JP. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol. 2001;211(4):161-171.
12. Nomi M, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol. 2001;21(24):8329-8335.
13. Lyashenko N, Weissenbock M, Sharir A, Erben RG, Minami Y, Hartmann C. Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev Dyn. 2010;239(8):2266-2277.
14. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011;35(10):1390-1394.
15. Fukuda T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008;105(8):3047-3052.
16. Daneshmanesh AH, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008;123(5):1190-1195.
17. Baskar S, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396-404.
18. Zhang S, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181(6):1903-1910.
19. Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015;150:143-148.
20. Cui B, et al. Targeting ROR1 inhibits epithelialmesenchymal transition and metastasis. Cancer Res. 2013;73(12):3649-3660.
21. Li X, et al. Activation of Wnt5a-Ror2 signaling associated with epithelial-to-mesenchymal transition of tubular epithelial cells during renal fibrosis. Genes Cells. 2013;18(7):608-619.
22. Zhang S, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancerstem-cell therapy. Proc Natl Acad Sci U S A. 2014;111(48):17266-17271.
23. Oishi I, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells. 2003;8(7):645-654.
24. Green JL, Inoue T, Sternberg PW. Opposing Wnt pathways orient cell polarity during organogenesis. Cell. 2008;134(4):646-656.
25. He F, et al. Wnt5a regulates directional cell migration and cell proliferation via Ror2-mediated noncanonical pathway in mammalian palate development. Development. 2008;135(23):3871-3879.
26. Ho HY, et al. Wnt5a-Ror-dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci U S A. 2012;109(11):4044-4051.
27. Ford CE, Qian Ma SS, Quadir A, Ward RL. The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 2013;133(4):779-787.
28. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006;4(4):e115.
29. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 2011;71(8):3132-3141.
30. Yamaguchi T, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21(3):348-361.
31. Kaucka M, et al. The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration. Cancer Res. 2013;73(5):1491-1501.
32. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629-635.
33. Nishita M, et al. Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization. Mol Cell Biol. 2010;30(14):3610-3619.
34. Lee JG, Heur M. Interleukin-1β-induced Wnt5a enhances human corneal endothelial cell migration through regulation of Cdc42 and RhoA. Mol Cell Biol. 2014;34(18):3535-3545.
35. Hofbauer SW, et al. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood. 2014;123(14):2181-2188.
36. Stacchini A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999;23(2):127-136.
37. Bertilaccio MT, et al. A novel Rag2-/-γc-/-xenograft model of human CLL. Blood. 2010;115(8):1605-1609.
38. Widhopf GF, et al. ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014;111(2):793-798.
39. Graversen JH, Sigurskjold BW, Thogersen HC, Etzerodt M. Tetranectin-binding site on plasminogen kringle 4 involves the lysine-binding pocket and at least one additional amino acid residue. Biochemistry. 2000;39(25):7414-7419.
40. Roszmusz E, Patthy A, Trexler M, Patthy L. Localization of disulfide bonds in the frizzled module of Ror1 receptor tyrosine kinase. J Biol Chem. 2001;276(21):18485-18490.
41. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 2008;18(11):536-544.
42. Manser E, et al. PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol Cell. 1998;1(2):183-192.
43. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6(2):167-180.
44. Matsuda T, et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev. 2001;105(1-2):153-156.
45. van Amerongen R, Berns A. Knockout mouse models to study Wnt signal transduction. Trends Genet. 2006;22(12):678-689.
46. Paganoni S, Bernstein J, Ferreira A. Ror1-Ror2 complexes modulate synapse formation in hippocampal neurons. Neuroscience. 2010;165(4):1261-1274.
47. Cha J, et al. Appropriate crypt formation in the uterus for embryo homing and implantation requires Wnt5a-ROR signaling. Cell Rep. 2014;8(2):382-392.
48. Liu Y, Rubin B, Bodine PV, Billiard J. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem. 2008;105(2):497-502.
49. Grumolato L, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 2010;24(22):2517-2530.
50. Petrova IM, Malessy MJ, Verhaagen J, Fradkin LG, Noordermeer JN. Wnt signaling through the Ror receptor in the nervous system. Mol Neurobiol. 2014;49(1):303-315.
51. Sato A, Yamamoto H, Sakane H, Koyama H, Kikuchi A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 2010;29(1):41-54.
52. Seifert M, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183-2198.
53. Bo H, et al. Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer. 2013;13:496.
54. Weeraratna AT, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279-288.
55. Fecteau JF, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124(10):1637-1644.
56. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94(11):3658-3667.
57. Qiao H, et al. Processing and subcellular trafficking of ER-tethered EIN2 control response to ethylene gas. Science. 2012;338(6105):390-393.